Our research is published in leading national and international journals to share the results of our studies with peers around the world.


Cook O, McIntyre M, Recoche K, Lee S. A clearer pathway—The future of the gynaecological oncology specialist nurse role. Collegian: Journal of the Royal College of Nursing Australia: 15 January 2020. https://doi.org/10.1016/j.colegn.2019.11.009


Clamp AR, James EC, McNeish IA, Dean A, Kim JW, O’Donnell DM, Hook J, Coyle C, Blagden S, Brenton JD, Naik R, Perren T, Sundar S, Cook AD,  Gopalakrishnan GS, Gabra H, Lord R, Dark G, Earl HM, Hall M, Banerjee S, Glasspool RM, Jones R, Williams S, Swart AM, Stenning S, Parmar M, Kaplan R,  Ledermann JA. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet Oncology. November 29, 2019. https://doi.org/10.1016/S0140-6736(19)32259-7

Antill Y, Kok PS, Stockler MR, Robledo KP, Yip S, Parry M, Smith D, Spurdle A, Barnes L, Friedlander M, Baron-Hay S, Shannon C, Coward J, Beale P, Goss G, Meniawy T, Andrews J, Kelly M and Mileshkin L on behalf of Australia New Zealand Gynaecological Oncology Group (ANZGOG). Updated results of activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: the phase 2 PHAEDRA trial (ANZGOG1601). Presented at ESMO Asia 2019. https://www.anzgog.org.au/wp-content/uploads/2019/11/PHAEDRA-Abstract-ESMOASIA19_updated-07Oct2019_FINAL.pdf

Ashley s. Felix, Erin M. McLaughlin, Bette J. Caan, David E. Cohn, Garnet L. Anderson, Electra D. Paskett. Guideline‐concordant endometrial cancer treatment and survival in the Women’s Health Initiative Life and Longevity After Cancer study. First published 16 October 2019 https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.32740

Mileshkin L, Barnes E, Moore K N, Gebski V, King M, Narayan K, Kolodziej I K, Sjoquist K, Fyles A, Small W, Gaffney D, Quinn M,  Andrews J, Thompson D,  Huh W, Carlson M, Disilvestro P A, Rischin D, Stockler M R, Monk B J. Disparities starting adjuvant chemotherapy for locally advanced cervix cancer in the international, academic, randomised, phase III OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274). Annals of Oncology, Volume 30, Issue Supplement_5, October 2019, mdz250.060, https://doi.org/10.1093/annonc/mdz250.060

Tang M, L. O’Connell R, Amant F, Beale P, McNally O, M. Sjoquist K, Grant P, Davis A, Sykes P, Mileshkin L, Moujaber T, J. Kennedy C,  de Fazio A, Tan K, Antill Y, Goh J, Bonaventura T, Scurry J, Friedlander M. PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. Gynecologic Oncology, Volume 154, Issue 3, September 2019, Pages 531-538, ISSN 0090-8258. https://doi.org/10.1016/j.ygyno.2019.06.011

Lee YC, Lheureux S, Raza Mirza M, Oza A. Targeted Therapy in Management of Endometrial Cancer. Management of Endometrial Cancer pp 249-276. https://doi.org/10.1007/978-3-319-64513-1_18

Webber K, Carolus E, Mileshkin L, Sommeijer D, McAlpine J, Bladgen S, Coleman RL, Herzog TJ, Sehouli J, Nasser S, Inci G, Friedlander M. OVQUEST – Life after the diagnosis and treatment of ovarian cancer – An international survey of symptoms and concerns in ovarian cancer survivors. Gynecologic Oncology August 2019. https://doi.org/10.1016/j.ygyno.2019.08.009

Embleton-Thirsk A, Deane E, Townsend S, Farrelly L, Popoola B, Parker J, Rustin G, Sydes M, Parmar M, Ledermann J, Kaplan R. Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization application. SAGE Journals 2019 July: https://doi.org/10.1177%2F1740774519862528

de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder Christine, Ottevanger PB, Ledermann J, Khaw P, D’Amico R, Fyles A, Baron MH, Jurgenliemk-Schuz I, Kitchener H, Nijman H, Wilson G, Brooks S, Gribaudo S, Provencher D, Hanzen C, Kruitwagen R, Smit V, Singh N, Do V, Lissoni A, Nout R, Feeney A, Verhoeven-Adema K, Putter H, Creutzberg C. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncology, 2019 July: http://dx.doi.org/10.1016/S1470-2045(19)30395-X

Mileshkin L, Edmondson R, O’Connell R, Sjoquist K, Andrews J, Jyothirmayi R, Beale P, Bonaventura T, Goh J, Hall M, Clamp A, Green J, Lord R, Amant F, Alexander L, Carty K, Scurry J, Millan D, Nottley S, Friedlander M. Phase 2 study of anastrazole in recurrent estrogen (ER) / progesterone (PR) positive endometrial cancer: The PARAGON trial – ANZGOG 0903. Gynecologic Oncology, Vol 154, July 2019: https://doi.org/10.1016/j.ygyno.2019.05.007

Narayan, K. Patient selection for clinical trials in endometrial cancer patients. Gynaecologic Oncology. 2019 June; Vol 154 (pg 276-277). https://doi.org/10.1016/j.ygyno.2019.04.644

Kok P, Beale P, O’Connell RL., Grant P, Bonaventura T, Scurry J, Antill Y, Goh J, Sjoquist K, DeFazio A,Mapagu C, Amant F, Friedlander M. PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression. J Gynecol Oncol. 2019 May(5):e86. https://doi.org/10.3802/jgo.2019.30.e86

Lindemann K, Beale P, Rossi E, Goh J, Vaughan M, Tenney M, Martyn J, Sommeijer D, Inglesias J, Kremmidiotis G, Simpson J, Doolin E, Lavranos T, Leske A, Veillard A, Espinoza D, Stockler M, Rischin D. (ANZGOG-1103) Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse. Cancer Chemotherapy and Pharmacology, Vol 83. 2019 January: https://doi.org/10.1007/s00280-018-3706-5


Wilson, M.K., R. Mercieca-Bebber, and M. Friedlander, A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer. J Gynecol Oncol, September 2018. 29(5): https://www.ncbi.nlm.nih.gov/pubmed/30022641

Sjoquist, K.M., L.R. Mileshkin, S. Ananda, C.M. Shannon, D. Bowtell, S. Yip, D. Espinoza, J.C. Goh, M.L. Harrison, M. Plebanski, V. Gebski, M.R. Stockler, K. Livingstone, M. Tang, and M. Friedlander, REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal (IP) bevacizumab (bev) for recurrent ascites in advanced, chemotherapy-resistant, epithelial ovarian cancer (CR-EOC). Journal of Clinical Oncology,June 2018. 36(15_suppl): p. 10097-10097DOI: http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.10097

Beesley, V.L., D.D. Smith, C.M. Nagle, M. Friedlander, P. Grant, A. DeFazio, P.M. Webb, and O.S. Group, Coping strategies, trajectories, and their associations with patient-reported outcomes among women with ovarian cancer. Support Care Cancer, June 2018 DOI: https://link.springer.com/article/10.1007/s00520-018-4284-0


King MT, Stockler MR, O’Connell RL, Buizen L, Joly F, Lanceley A, Hilpert F, Okamoto A, Aotani E, Bryce J, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Sehouli J, Feeney A, Berton-Rigaud D, Costa DSJ, Friedlander ML; GCIG Symptom Benefit group. Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer. Qual Life Res. 2017 Dec 16. https://doi.org/10.1007/s11136-017-1729-8 [Epub ahead of print] PubMed PMID: 29248998.

de Boer SM, Wortman BG, Bosse T, Powell ME, Singh N, Hollema H, Wilson G, Chowdhury MN, Mileshkin L, Pyman J, Katsaros D, Carinelli S, Fyles A, McLachlin CM, Haie-Meder C, Duvillard P, Nout RA, Verhoeven-Adema KW, Putter H, Creutzberg CL, Smit VTHBM; PORTEC study group. Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer. Ann Oncol. 2017 Nov 27. https://doi.org/10.1093/annonc/mdx753 PubMed PMID: 29190319.

C.A. Hamilton, A. Miller, Y. Casablanca, N.S. Horowitz, B. Rungruang, T.C. Krivak, S.D. Richard, N. Rodriguez, M.J. Birrer, F.J. Backes, M.A. Geller, M. Quinn, M.J. Goodheart, D.G. Mutch, J.J. Kavanagh, G.L. Maxwell, M.A. Bookman, Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study, Gynecologic Oncology, Available online 28 November 2017, ISSN 0090-8258, https://doi.org/10.1016/j.ygyno.2017.11.018

M A Bookman, A Okamoto, G Stuart, N Yanaihara, D Aoki, M Bacon, K Fujiwara, A González-Martín, P Harter, J W Kim, J Ledermann, E Pujade-Lauraine, M Quinn, K Ochiai, participants of the 5th Ovarian Cancer Consensus Conference; Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference, Annals of Oncology, Volume 28, Issue suppl_8, 1 November 2017, Pages viii30–viii35, https://doi.org/10.1093/annonc/mdx449

Park, S.B., J.B. Kwok, R. Asher, C.K. Lee, P. Beale, F. Selle, and M. Friedlander, Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial. Ann Oncol, November 201728(11): https://www.ncbi.nlm.nih.gov/pubmed/29117336

Lim, K., van Dyk, S., Khaw, P., Veera, J., Mileshkin, L., Ohanessian, L., Harrison, M. and Vinod, S. K. (2017), Patterns of practice survey for brachytherapy for cervix cancer in Australia and New Zealand. J Med Imaging Radiat Oncol.October 2017  https://www.ncbi.nlm.nih.gov/pubmed/28470944

Mercieca-Bebber, R., Friedlander, M., Calvert, M. et al. J A systematic evaluation of compliance and reporting of patient-reported outcome endpoints in ovarian cancer randomised controlled trials: implications for generalisability and clinical practice October (2017) 1: 5. https://doi.org/10.1186/s41687-017-0008-3

Roncolato FT, Berton-Rigaud D, O’Connell R, Lanceley A, Sehouli J, Buizen L, Okamoto A, Aotani E, Lorusso D, Donnellan P, Oza A, Avall-Lundqvist E, Berek J, Hilpert F, Ledermann JA, Kaminsky MC, Stockler MR, King MT, Friedlander M. Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) – Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS). Gynecol Oncol. 2017 Oct 26. pii: S0090-8258(17)31422-1. https://doi.org/10.1016/j.ygyno.2017.10.019

Friedlander, M., R.L. Mercieca-Bebber, and M.T. King, Patient-reported outcomes (PRO) in ovarian cancer clinical trials-lost opportunities and lessons learned. Ann Oncol, October 201727 Suppl 1https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934909/

Clamp, A.R., I. McNeish, A. Dean, D. Gallardo, J. Weon-Kim, D. O’Donnell, J. Hook, C. Coyle, S.P. Blagden, J. Brenton, R. Naik, T. Perren, S. Sundar, A. Cook, E. James, A.M. Swart, S. Stenning, R. Kaplan, and J. Ledermann, 929O_PRICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysis. Annals of Oncology, September 201728(suppl_5): https://oncologypro.esmo.org/Meeting-Resources/ESMO-2017-Congress/BRIM8-a-randomized-double-blind-placebo-controlled-study-of-adjuvant-vemurafenib-in-patients-pts-with-completely-resected-BRAFV600-melanoma-at-high-risk-for-recurrence

Cohen PA, Brand A, Sykes P, et al. Excisional treatment in women with cervical adenocarcinoma in situ (AIS): a prospective randomised controlled non-inferiority trial to compare AIS persistence/recurrence after loop electrosurgical excision procedure with cold knife cone biopsy: protocol for a pilot study. BMJ Open August 2017;7:e017576. https://doi.org/10.1136/bmjopen-2017-017576

Lindemann K, Kok PS, Stockler M, Jaaback K, Brand A. Enhanced recovery after surgery for advanced ovarian cancer: A systematic review of interventions trialed. Int J Gynecol Cancer. 2017 Jul;27(6):1274-1282. https://doi.org/10.1097/IGC.0000000000000981Review. PubMed PMID: 28498237.

Lindemann K, Kok PS, Stockler M, Sykes P, Brand A. Enhanced recovery after surgery for suspected ovarian malignancy: A survey of perioperative practice amongst gynecogical oncologists in Australia and New Zealand to inform a clinical trial. Int J Gynecol Cancer. 2017 Jun;27(5):1046-1050. doi: https://doi.org/10.1097/IGC.0000000000000982

Florence Joly, Felix Hilpert, Aikou Okamoto, Gavin Stuart, Kasunori Ochiai, Michael Friedlander, Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer, European Journal of Cancer, Volume 78, June 2017, Pages 133-138, ISSN 0959-8049, https://doi.org/10.1016/j.ejca.2017.03.019

Bonaventura A1, OʼConnell RL, Mapagu C, Beale PJ, McNally OM, Mileshkin LR, Grant PT, Hadley AM, Goh JCH, Sjoquist KM, Martyn J, DeFazio A, Scurry J, Friedlander ML; Paragon Investigators. Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer. Int J Gynecol Cancer. Jun 2017; 27(5):900–906, https://doi.org/10.1097/IGC.0000000000000978

Roncolato FT, Joly F, O’Connell R, Lanceley A, Hilpert F, Buizen L, Okamoto A, Aotani E, Pignata S, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Heitz F, Feeney A, Berton-Rigaud D, Stockler MR, King M, Friedlander M; GCIG Symptom Benefit group. Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.Oncologist. 2017 Jun 8. pii: theoncologist.2017-0047. https://doi.org/10.1634/theoncologist.2017-0047  [Epub ahead of print] PMID: 28596446

Lindemann K, Kok PS, Stockler M, Jaaback K, Brand A. Enhanced recovery after surgery programs for ovarian cancer – a systematic review to identify candidate interventions. Int J Gynecol Cancer. 2017 May 12. https://doi.org/10.1097/IGC.0000000000000981

Yoland Catherine Antill, Martin R. Stockler, Peey Sei Kok, Kristy Pamela Robledo, Kim Gillies, John Stark, Sonia Yip, Linda R. Mileshkin, and Australia New Zealand Gynaecological Oncology Group (ANZGOG). A phase II trial of durvalumab (Medi 4736) in advanced endometrial cancer: PHAEDRA. Journal of Clinical Oncology May 2017 http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.TPS5614

McGee, M. Bookman, P. Harter, C. Marth, I. McNeish, K. N. Moore, A. Poveda, F. Hilpert, K. Hasegawa, M. Bacon, C. Gatsonis, A. Brand, F. Kridelka, J. Berek, N. Ottevanger, T. Levy, S. Silverberg, B.-G. Kim, H. Hirte, A. Okamoto, G. Stuart, K. Ochiai, and on behalf of the participants of the 5th Ovarian Cancer Consensus Conference; Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors. Ann Oncol January 2017 mdx010. https://doi.org/10.1093/annonc/mdx010


Wilson, E. Pujade-Lauraine, D. Aoki, M. R. Mirza, D. Lorusso, A. M. Oza, A. du Bois, I. Vergote, A. Reuss, M. Bacon, M. Friedlander, D. Gallardo-Rincon, F. Joly, S.-J. Chang, A. M. Ferrero, R. J. Edmondson, P. Wimberger, J. Maenpaa, D. Gaffney, R. Zang, A. Okamoto, G. Stuart, K. Ochiai, and on behalf of the participants of the Fifth Ovarian Cancer Consensus Conference; Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease.Ann Oncol 2016 December mdw663. https://doi.org/10.1093/annonc/mdw663

Rungruang BJ, Miller A, Krivak TC, Horowitz NS, Rodriguez N, Hamilton CA, Backes FJ, Carson LF, Friedlander M, Mutch DG, Goodheart MJ, Tewari KS, Wenham RM, Bookman MA, Maxwell GL, Richard SD. What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study. Cancer. 2017 May 15; 123(6):985-993. https://doi.org/10.1002/cncr.30414 Epub 2016 Nov 16.

Pulford DJ, Harter P, Floquet A, Barrett C, Suh DH, Friedlander M, Arranz JA, recurrent-estrogen-ER-progesterone-PR-positive-endometrial-cancer-The-PARAGON-trial-ANZGOG-0903%2epdf%26hl%3den%26sa%3dX%26d%3d4515451377253725257%26scisig%3dAAGBfm05euisB4mEV4UXcVkDzyPTI0%5fOpA%Hasegawa K, Tada H, Vuylsteke P, Mirza MR, Donadello N, Scambia G, Johnson T, Cox C, Chan JK, Imhof M, Herzog TJ, Calvert P, Wimberger P, Berton-Rigaud D, Lim MC, Elser G, Xu CF, du Bois A. Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study. BMC Med Ethics. 2016 Oct 21;17(1):63. PubMed PMID: 27769273. https://doi.org/10.1186/s12910-016-0144-y

Jameson MG, McNamara J, Bailey M, Metcalfe PE, Holloway LC, Foo K, Do V, Mileshkin L, Creutzberg CL, Khaw P. Results of the Australasian (Trans-Tasman Oncology Group) radiotherapy benchmarking exercise in preparation for participation in the PORTEC-3 trial. J Med Imaging Radiat Oncol. 2016 Aug; 60(4):554-9. https://doi.org/10.1111/1754-9485.12447 Epub 2016 Apr 5.

de Boer, S.M., M.E. Powell, L. Mileshkin, D. Katsaros, P. Bessette, C. Haie-Meder, P.B. Ottevanger, J.A. Ledermann, P. Khaw, A. Colombo, A. Fyles, M.H. Baron, H.C. Kitchener, H.W. Nijman, R.F. Kruitwagen, R.A. Nout, K.W. Verhoeven-Adema, V.T. Smit, H. Putter, C.L. Creutzberg, and P.s. group, Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol,August  201617(8): https://www.ncbi.nlm.nih.gov/pubmed/27397040

Mercieca-Bebber, R., Friedlander, M., Kok, PS. et al. The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols. (June 2016) 25: 2457. https://doi.org/10.1007/s11136-016-1339-x